Salvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy

Thoracic reRT is a safe treatment option associated with long-term cure in select patients. Immunotherapy consolidation was associated with improved clinical outcomes.

Authors

Institutions

Publication Details

Journal
Radiotherapy and Oncology
Published
2025-04-27
DOI
https://doi.org/10.1016/j.radonc.2025.110911
Citations
3
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Salvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy

Jeffrey D. Bradley, William P. Levin, Michelle Iocolano, Steven J. Feigenberg et al.
3 citations
Radiotherapy and Oncology
Lung Cancer Diagnosis and Treatment
4.56
article

Salvage thoracic reirradiation for recurrent non-small cell lung cancer: Clinical efficacy and the impact of consolidative immunotherapy

Jeffrey D. Bradley, William P. Levin, Michelle Iocolano, Steven J. Feigenberg, Cole Friedes, Keith A. Cengel, Nikhil Yegya‐Raman, J.R. Rocchetti
article en
3 citations

Abstract

Thoracic reRT is a safe treatment option associated with long-term cure in select patients. Immunotherapy consolidation was associated with improved clinical outcomes.

Radiotherapy and OncologyVol. 208
University of Pennsylvania (US)
Openalex Percentile: Top 6%
Lung Cancer Diagnosis and Treatment
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.